Personalized treatment with atypical antipsychotic medications

Advances in Therapy

Volumn 24, Issue 4, 2007, Pages 721-740

  Kim, Edward ^a   Levy, Richard ^b,d   Pikalov, Andrei ^c  

^a BRISTOL MYERS SQUIBB   (United States)

^b Levy Consulting   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^d NONE   (United States)

Author keywords

Atypical antipsychotics; CATIE; Fail first; Formulary; Personalized medicine; Pharmaceutical policy; Schizophrenia; Therapeutic substitution

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FLUOXETINE; GLUCOCORTICOID; MACROLIDE; MOOD STABILIZER; NERVE GROWTH FACTOR; OLANZAPINE; PALIPERIDONE; PAROXETINE; PERPHENAZINE; PLACEBO; PROTEINASE INHIBITOR; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; ZIPRASIDONE; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; CYTOCHROME P450 2D6; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ANTICHOLINERGIC EFFECT; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; CELL SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; EXTRAPYRAMIDAL SYMPTOM; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HEADACHE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH PROGRAM; HOSPITAL COST; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MEDICAID; METABOLIC SYNDROME X; MYOCARDITIS; NAUSEA; PATIENT COMPLIANCE; PHARMACOGENOMICS; PRESCRIPTION; PREVALENCE; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RECURRENCE RISK; REIMBURSEMENT; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; TARDIVE DYSKINESIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VULNERABLE POPULATION; WEIGHT GAIN; AGED; COST BENEFIT ANALYSIS; DRUG INTERACTION; GENETICS; GERIATRICS; INSURANCE; METABOLISM; MINORITY GROUP; PHARMACOGENETICS; PUBLICATION;

AGED; ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FORMULARIES; GERIATRICS; HUMANS; INSURANCE CARRIERS; MINORITY GROUPS; PATIENT COMPLIANCE; PHARMACOGENETICS; SCHIZOPHRENIA; VARIATION (GENETICS);

EID: 38449084710     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02849966     Document Type: Review

References (55)